Rimegepant: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), NICE (England) and SMC (Scotland) recommended or restricted rimegepant, while PBAC (Australia) and ZIN (Netherlands) did not recommend it.
The record spans 3.4 years, opening at AWMSG (Wales) on 10 Jun 2022 and running to 20 Nov 2025.
NICE (England) changed its position: recommended on 5 Jul 2023, restricted by 18 Oct 2023.
No assessment is on file from HAS (France) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
Not every gap is a refusal: for rimegepant, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 18 of 19 records date from 2023 or later.
6 distinct indication wordings are recorded for rimegepant by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 19 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess rimegepant, on 10 Jun 2022; G-BA (Germany) did not open a file until 20 Nov 2025 — a wide spread of 3.4 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 8 of 19 dated records fall in 2023 alone.
Restriction is doing real work here: 4 of 13 decisive outcomes narrowed rimegepant to a subgroup rather than accepting or refusing it outright, at NICE (England), SMC (Scotland) and TLV (Sweden).
6 of the 10 agencies here assessed rimegepant more than once, CIPM (Spain) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for rimegepant.
The full ledger for rimegepant reads 5 recommended, 4 not recommended, 4 restricted and 3 no benefit, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 20 Nov 2025 | Vydura — benefit assessment §35a | added benefit: not proven | source |
| TLV (Sweden) | 10 Nov 2025 | Vydura får inte ändrad subventionsbegränsning | rejection or exclusion | source |
| CHUIKYO (Japan) | 5 Nov 2025 | ナルティーク: cost-effectiveness evaluation (new product, high price or high sales) | evaluation under way | source |
| CIPM (Spain) | 19 Jun 2025 | Indicación terapéutica autorizada: - tratamiento agudo de la migraña con o sin aura en adultos - tratamiento preventivo … | financed by the SNS · art. 92 a, c | source |
| AIFA (Italy) | 17 Jun 2025 | Trattamento acuto di emicrania con o senza aura negli adulti che non hanno risposto adeguatamente alla terapia con tript… | innovative status not granted · reimbursed class A | source |
14 further decisions for rimegepant, across 8 agencies, are not shown here. They include the most recent record on file, 20 Nov 2025 from G-BA (Germany); its outcome is in the subscriber dataset. They link to 13 further source documents.
Related molecules
- galcanezumab — same ATC class N02C — Analgesics
- erenumab — same ATC class N02C — Analgesics
- fremanezumab — same ATC class N02C — Analgesics
- atogepant — same ATC class N02C — Analgesics
- eptinezumab — same ATC class N02C — Analgesics
- sumatriptan — same ATC class N02C — Analgesics
Coverage: 19 decisions for rimegepant from 10 agencies, 2022 to 2025. Data to 7 Sep 2026. ATC class N02C — Analgesics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.